Use of Trastuzumab to Induce Increased ER Expression in ER-negative/Low, Her-2/Neu Positive Breast Cancer
Status:
Terminated
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
The majority pf breast cancers present as ER-positive, many of which are able to be targeted
with multiple hormonal therapies. Altering ER-negative tumors to increase ER expression has
the potential to benefit patients by making hormonal therapies a therapeutic option and
possibly improving their overall prognosis.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center